SIENA, SALVATORE
SIENA, SALVATORE
Dipartimento di Oncologia ed Emato-Oncologia
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
2024 A. Sogari, E. Rovera, G. Grasso, E. Mariella, N.M. Reilly, S. Lamba, G. Mauri, E. Durinikova, P.P. Vitiello, A. Lorenzato, M. Avolio, E. Piumatti, E. Bonoldi, M.C. Aquilano, S. Arena, A. Sartore-Bianchi, S. Siena, L. Trusolino, M. Donalisio, M. Russo, F. Di Nicolantonio, D. Lembo, A. Bardelli
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
2024 B.T. Li, F. Meric-Bernstam, A. Bardia, Y. Naito, S. Siena, P. Aftimos, I. Anderson, G. Curigliano, M. de Miguel, M. Kalra, D. Oh, J.O. Park, S. Postel-Vinay, S.Y. Rha, T. Satoh, I. Spanggaard, F. Michelini, A. Smith, K.K. Machado, C. Saura
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial
2024 D. Ciardiello, E. Martinelli, T. Troiani, G. Mauri, D. Rossini, G. Martini, S. Napolitano, V. Famiglietti, S. Del Tufo, G. Masi, D. Santini, A. Avallone, F. Pietrantonio, S. Lonardi, M. Di Maio, M.G. Zampino, N. Fazio, A. Bardelli, S. Siena, C. Cremolini, A. Sartore-Bianchi, F. Ciardiello
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers
2024 G. Mauri, G. Patelli, L. Roazzi, E. Valtorta, A. Amatu, G. Marrapese, E. Bonazzina, F. Tosi, K. Bencardino, G. Ciarlo, E. Mariella, S. Marsoni, A. Bardelli, E. Bonoldi, A. Sartore-Bianchi, S. Siena
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting
2024 A. Hackshaw, O. Fajardo, U. Dafni, H. Gelderblom, P. Garrido, S. Siena, M.H. Taylor, W. Bordogna, C. Nikolaidis
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
2024 D. Ciardiello, G. Mauri, A. Sartore-Bianchi, S. Siena, M.G. Zampino, N. Fazio, A. Cervantes
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
2024 Y. Fan, A. Drilon, C. Chiu, H.H.F. Loong, S. Siena, M. Krzakowski, R. Dziadziuszko, H. Zeuner, C. Xue, M.G. Krebs
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
2024 L. Roazzi, G. Patelli, K.B. Bencardino, A. Amatu, E. Bonazzina, F. Tosi, B. Amoruso, A. Bombelli, S. Mariano, S. Stabile, C. Porta, S. Siena, A. Sartore-Bianchi
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024 M. Niger, F. Nichetti, L. Fornaro, C. Pircher, F. Morano, F. Palermo, L. Rimassa, T. Pressiani, R. Berardi, A.C. Gardini, E. Sperti, L. Salvatore, D. Melisi, F. Bergamo, S. Siena, S. Mosconi, R. Longarini, G. Arcangeli, S. Corallo, L. Delliponti, S. Tamberi, E. Fea, G. Brandi, I.G. Rapposelli, M. Salati, P. Baili, R. Miceli, S. Ljevar, I. Cavallo, E. Sottotetti, A. Martinetti, M.D.D. Busset, C. Sposito, M. Di Bartolomeo, F. Pietrantonio, F. de Braud, V. Mazzaferro
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
2023 J.H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, C. Wu, A.S. Paulson, J.M. Hubbard, A.L. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H. Lenz, K.K. Ciombor, E. Elez, D.L. Bajor, C. Cremolini, F. Sanchez, M. Stecher, W. Feng, T.S. Bekaii-Saab
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer
2023 E. Van Cutsem, R. Yaeger, J. Delord, J. Tabernero, L.L. Siu, M. Ducreux, S. Siena, E. Elez, S. Kasper, T. Zander, N. Steeghs, D. Murphy, M. Edwards, Z.A. Wainberg
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
2023 E.G. Pizzutilo, A.G. Agostara, L. Roazzi, R. Romanò, V. Motta, C. Lauricella, G. Marrapese, G. Cerea, D. Signorelli, S. Marco Veronese, L. Giuseppina Giannetta, A. Sartore-Bianchi, S. Siena
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
2023 E.G. Pizzutilo, R. Romanò, L. Roazzi, A.G. Agostara, S. Oresti, A. Zeppellini, L. Giannetta, G. Cerea, D. Signorelli, S. Siena, A. SARTORE BIANCHI
Circulating tumor DNA to drive treatment in metastatic colorectal cancer
2023 G. Patelli, G. Mauri, F. Tosi, A. Amatu, K. Bencardino, E. Bonazzina, E.G. Pizzutilo, F. Villa, G. Calvanese, A.G. Agostara, S. Stabile, S. Ghezzi, G. Crisafulli, F. Di Nicolantonio, S. Marsoni, A. Bardelli, S. Siena, A. Sartore-Bianchi
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
2023 A. Petrelli, S. Rizzolio, F. Pietrantonio, S.E. Bellomo, M. Benelli, L. De Cecco, D. Romagnoli, E. Berrino, C. Orrù, S. Ribisi, D. Moya-Rull, C. Migliore, D. Conticelli, I.M. Maina, E. Puliga, V. Serra, B. Pellegrino, A. Llop-Guevara, A. Musolino, S. Siena, A. Sartore-Bianchi, M. Prisciandaro, F. Morano, M. Antista, U. Fumagalli, G. De Manzoni, M. Degiuli, G.L. Baiocchi, M.F. Amisano, A. Ferrero, C. Marchiò, S. Corso, S. Giordano
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2023 F. Meric-Bernstam, V. Makker, A. Oaknin, D. Oh, S. Banerjee, A. González-Martín, K.H. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, Y. Ma, S. Puvvada, N. Shire, J. Lee
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review
2023 C. Vaghi, G. Mauri, A.G. Agostara, G. Patelli, E.G. Pizzutilo, Y. Nakamura, T. Yoshino, S. Siena, A. Sartore-Bianchi
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
2023 T. Yoshino, M. Di Bartolomeo, K. Raghav, T. Masuishi, F. Loupakis, H. Kawakami, K. Yamaguchi, T. Nishina, Z. Wainberg, E. Elez, J. Rodriguez, M. Fakih, F. Ciardiello, K. Saxena, K. Kobayashi, E. Bako, Y. Okuda, G. Meinhardt, A. Grothey, S. Siena
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
2023 E. Van Cutsem, M. di Bartolomeo, E. Smyth, I. Chau, H. Park, S. Siena, S. Lonardi, Z.A. Wainberg, J. Ajani, J. Chao, Y. Janjigian, A. Qin, J. Singh, F. Barlaskar, Y. Kawaguchi, G. Ku
Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea
2023 G. Mauri, M. Pedrani, S. Ghezzi, K. Bencardino, S. Mariano, E. Bonazzina, F. Serra, P. Pedrazzoli, R. Caccialanza, G.M. Cavestro, S. Siena, S. Artale, A. Sartore-Bianchi